Acute left ventricular dysfunction induced by a panHER and VEGFR tyrosine kinase inhibitor in a phase I trial

Left Ventricular Dysfunction ◽

Phase I Trial ◽

Ventricular Dysfunction ◽

Kinase Inhibitor ◽

Left Ventricular ◽

A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-18-1881 ◽

2019 ◽

Vol 25 (18) ◽

pp. 5475-5484 ◽

Cited By ~ 6

Author(s):

Razelle Kurzrock ◽

Douglas W. Ball ◽

Marianna L. Zahurak ◽

Barry D. Nelkin ◽

Vivek Subbiah ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Receptor Tyrosine Kinase ◽

Phase I Trial ◽

Kinase Inhibitor ◽

Mek Inhibitor ◽

Vegf Receptor ◽

Advanced Solid Tumors ◽

Differentiated Thyroid Cancers

Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor

Investigational New Drugs ◽

10.1023/b:drug.0000047103.64335.b0 ◽

2005 ◽

Vol 23 (1) ◽

pp. 31-37 ◽

Cited By ~ 72

Author(s):

John L. Marshall ◽

Hedy Kindler ◽

John Deeken ◽

Pankaj Bhargava ◽

Nicholas J. Vogelzang ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Phase I Trial ◽

Kinase Inhibitor ◽

Neurotrophin Receptor

A phase I dose escalation trial of the VEGFR tyrosine kinase inhibitor, PTK787/ ZK222584 (PTK/ZK), used in combination with paclitaxel in patients with advanced solid tumors with pharmacokinetic (PK) analysis

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.14521 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 14521-14521

Author(s):

S. R. Malireddy ◽

E. G. Chiorean ◽

A. Younger ◽

D. Jones ◽

M. Waddell ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Solid Tumors ◽

Dose Escalation ◽

Kinase Inhibitor ◽

Advanced Solid Tumors ◽

38 POSTER Phase I and pharmacological study of KRN951, a potent VEGFR tyrosine kinase inhibitor given in a 4 week on, 2 week off schedule in patients with advanced solid tumors

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(06)70044-1 ◽

2006 ◽

Vol 4 (12) ◽

pp. 16 ◽

Cited By ~ 1

Author(s):

F.A.L.M. Eskens ◽

M.J.A. de Jonge ◽

L. van Doorn ◽

T. Isoe ◽

K. Hayashi ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Solid Tumors ◽

Kinase Inhibitor ◽

Pharmacological Study ◽

Advanced Solid Tumors ◽

49 POSTER Analyses of pharmacodynamic (PD) assessments collected during expanded cohorts (EC) of a phase I trial with OSI-930, a multi-targeted oral tyrosine kinase inhibitor (TKI)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(08)71981-5 ◽

2008 ◽

Vol 6 (12) ◽

pp. 19

Author(s):

J. Spratlin ◽

H.T. Arkenau ◽

S. George ◽

N.J. Serkova ◽

M. Germuska ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Phase I Trial ◽

Kinase Inhibitor

A Phase I Trial of Incorporating Natural Killer (K-NK) Cells for Patients with Chronic Myeloid Leukemia (CML) and Molecular Residual Disease after Tyrosine Kinase Inhibitor (TKI) Therapy

Transplantation and Cellular Therapy ◽

10.1016/s2666-6367(21)00198-6 ◽

2021 ◽

Vol 27 (3) ◽

pp. S161

Author(s):

Lindsay Rein ◽

David A Rizzieri

Keyword(s):

Chronic Myeloid Leukemia ◽

Tyrosine Kinase ◽

Phase I ◽

Nk Cells ◽

Natural Killer ◽

Myeloid Leukemia ◽

Phase I Trial ◽

Kinase Inhibitor ◽

Residual Disease

Pegilodecakin as monotherapy or in combination with anti‐PD ‐1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study

International Journal of Cancer ◽

10.1002/ijc.33556 ◽

2021 ◽

Author(s):

Nizar M. Tannir ◽

Kyriakos P. Papadopoulos ◽

Deborah J. Wong ◽

Raid Aljumaily ◽

Annie Hung ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Tyrosine Kinase ◽

Phase I ◽

Cell Carcinoma ◽

Renal Cell ◽

Phase I Study ◽

Kinase Inhibitor ◽

Heavily Pretreated ◽

Pretreated Patients

Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study

Investigational New Drugs ◽

10.1007/s10637-021-01093-7 ◽

2021 ◽

Author(s):

Katrina S. Pedersen ◽

Patrick M. Grierson ◽

Joel Picus ◽

A. Craig Lockhart ◽

Bruce J. Roth ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Kinase Inhibitor

VEGFR tyrosine kinase inhibitor II (VRI) induced vascular insufficiency in zebrafish as a model for studying vascular toxicity and vascular preservation

Toxicology and Applied Pharmacology ◽

10.1016/j.taap.2014.09.005 ◽

2014 ◽

Vol 280 (3) ◽

pp. 408-420 ◽

Cited By ~ 26

Author(s):

Shang Li ◽

Yuan Ye Dang ◽

Ginny Oi Lam Che ◽

Yiu Wa Kwan ◽

Shun Wan Chan ◽

...

Keyword(s):

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Vascular Toxicity ◽

Vascular Insufficiency ◽

Vascular Preservation ◽

2038 A Phase I/II Study of Oral Pazopanib, a Receptor Tyrosine Kinase Inhibitor, in Neovascular Age Related Macular Degeneration

SciVee ◽

10.4016/40519.01 ◽

2012 ◽

Author(s):

Jason Slakter

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Macular Degeneration ◽

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Age Related Macular Degeneration ◽

Receptor Tyrosine Kinase Inhibitor ◽

Age Related